Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
Human testing has begun of ISIS-SOD1-Rx, a compound designed to block production of a toxic protein in people with the SOD1-related form of familial (inherited) ALS
Posted on Friday, March 5, 2010 - 15:20, By: Amy Madsen
Isis Pharmaceuticals of Carlsbad, Calif., has begun a phase 1 clinical trial of its experimental compound ISIS-SOD1-Rx in people with familial (inherited) ALS caused by toxic SOD1 protein molecules.
Ten leaders in the field of ALS research put their heads together on Oct. 24, 2009
Posted on Friday, October 30, 2009 - 13:35, By: ALSN Staff
An all-day "think tank" to consider priorities for amyotrophic lateral sclerosis (ALS) research based on the latest information was conducted with ten of the leading scientists and clinicians in the field and senior MDA staff in Tucson, Ariz., on Saturday, Oct. 24, 2009.
The first ALS trial to block abnormal SOD1 protein using ‘antisense’ is set to open by the end of 2009
Posted on Monday, October 19, 2009 - 13:47, By: ALSN Staff
A phase 1 clinical trial of the experimental drug ISIS-SOD1-Rx in patients with the SOD1-related type of familial (inherited) amyotrophic lateral sclerosis (ALS) is expected to begin before the end of 2009 at Washington University in St. Louis, Massachusetts General Hospital in Boston and four...